Axum Pharmaceuticals

Axum Pharmaceuticals is a specialty pharmaceutical company focused on the development of treatments for Central Nervous System (CNS) disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and sleep disorders. The company leverages the 505(b)(2) regulatory pathway to develop differentiated products based on known chemical entities, aiming to improve efficacy, safety, and patient adherence. Its lead candidates, AXM-01 and AXM-02, are designed to provide optimized delivery profiles for stimulants and other CNS-active compounds. Axum is headquartered in New Jersey and managed by industry veterans with significant experience in the CNS space. The company's strategy involves identifying unmet clinical needs in established markets and applying formulation expertise to create value-added therapeutic options.